Side-by-side · Research reference

LivagenvsSemax

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED20/32 cited

BHuman-MechanisticAUTO-DRAFTED12/39 cited

Livagen

Khavinson Bioregulator · Hepatoprotective Tetrapeptide

50%Dipeptidase inhibitionTimofeeva 2005

Oral / SQRoutes tested

LiverTarget tissueKhavinson 2001

Oral or SQ · Tissue-specific to liver

Semax

Cognitive enhancer · Russian Pharma

200–600 mcg/doseIntranasalKaplan 2017

HumanMechanisticKaplan 2017

~30 minOnset

Intranasal · 2–3×/day during cognitive demand

01Mechanism of Action

Parameter

Livagen

Semax

Primary target

Hepatocyte protein synthesis machineryBrodskiĭ 2001

BDNF / NGF expression + monoamine modulationKaplan 2017

Pathway

Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalizationBrodskiĭ 2001 Khavinson 2001

↑ BDNF + NGF synthesis + 5-HT modulation → neuroplasticity + anxiolysis + cognitive enhancementKaplan 2017

Downstream effect

Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes

Improved memory + attention; reduced anxiety; neuroprotection in ischemiaKaplan 2017

Feedback intact?

—

Origin

Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil)

Synthetic 7-AA peptide derived from ACTH(4-7) with C-terminal Pro-Gly-Pro stabilising tailKaplan 2017

Antibody development

—

02Dosage Protocols

Parameter

Livagen

Semax

Animal dose (oral)

Not specified in abstracts; 2-week administration protocolTimofeeva 2005

Per os administration in rats.

—

Duration (experimental)

2 weeks (enzyme study); up to 24 months (cell culture)Timofeeva 2005 Brodskiĭ 2001

—

Route

Oral or subcutaneous

Resists peptidase hydrolysis, enabling oral bioavailability.Timofeeva 2005

—

Evidence basis

Animal models (rats, 1–24 months age); in vitro hepatocyte cultureTimofeeva 2005 Brodskiĭ 2001 Khavinson 2002

Human-mechanistic + Russian clinicalKaplan 2017

Human data

None in provided literature

—

Standard dose

—

200–600 mcg / dose intranasalKaplan 2017

Frequency

—

2–3× per day during cognitive demand

Lower / starter dose

—

100 mcg / dose

Duration

—

10–14 day cycles, repeated PRN

Reconstitution

—

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

Timing

—

Morning + early afternoon

Half-life

—

Short plasma; CNS effect lasts ~3–6 hr

04Side Effects & Safety

Parameter

Livagen

Semax

Reported adverse effects

None documented in animal studies

—

Human safety data

No human trials in provided literature

—

Peptide hydrolysis

Weakly hydrolyzed; minimal breakdown by intestinal enzymesTimofeeva 2005

—

Nasal irritation

—

Mild burning or congestion (transient)

Sleep disruption

—

Late-day dosing may interfere with sleep

Headache

—

Uncommon, transient

Long-term safety

—

Limited Western RCT data

Pregnancy / OB

—

Avoid

Absolute Contraindications

Livagen

—

Semax

·Pregnancy / breastfeeding

Relative Contraindications

Livagen

—

Semax

·Active psychiatric instability
·Concurrent strong stimulants

05Administration Protocol

Parameter

Livagen

Semax

1. Route selection

Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments.Timofeeva 2005 Khavinson 2001

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

2. Timing

No specific timing documented. Two-week protocols used in animal models with daily administration.Timofeeva 2005

Intranasal — 2–3 sprays per nostril per dose. Tilt head slightly back.

3. Age-dependent response

Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings.Timofeeva 2005

Morning + early afternoon. Avoid evening (sleep disruption).

4. Storage

—

Refrigerate after reconstitution; light-protected.

5. Caveat

—

Cycle on/off to avoid neurochemical adaptation.

06Stack Synergy

Livagen

— no documented stacks

Semax

+ Selank

Moderate

View Selank →

Semax (cognitive enhancer, BDNF/NGF) and Selank (anxiolytic + immune) form the canonical Russian "neuro stack" — both intranasal peptide bioregulators with complementary axes. Semax for cognitive demand; Selank for stress mitigation.

Semax: 200–600 mcg intranasal · morning + afternoon
Selank: 150–300 mcg intranasal · midday + early evening
Primary benefit: Cognitive enhancement + stress mitigation

Kaplan 2017 Zaderej 2014